MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to announce it has completed the first phase of its series of studies with the University of Melbourne to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD). On July 2, 2021, the Company entered... Read More

MIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today that it received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Ehave's Investigational New Drug ("IND") application is complete. The FDA authorized Ehave to proceed with its clinical study,... Read More

MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”) , a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will accept delivery of its KetaDASH Mobile Unit in Miami Beach Florida on June 10, 2022. The KetaDASH Mobile Unit is a custom high-end medical van utilizing KetaDASH’s software platform.... Read More

AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinic Genetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today that its Mycotopia Therapies (OTC: TPIA) subsidiary has signed a definitive agreement to complete a triangular merger with Ei.Ventures , an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology, to form PSLY.COM. The companies anticipate closing the... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data... Read More

Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today plans to enter the $13 billion medicinal mushroom market with HAVN Life Sciences ' biopharmaceuticals and Ei.Ventures MANA products. In advance of its acquisition of Ei.Ventures and plans to form PSLY.COM, Mycotopia Therapies has expanded its supply... Read More

Ehave, Inc ., (OTC Pink: EHVVF) (the "Company"), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it will participate in Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 7-9, 2021. ""We are pleased to have the opportunity to participate as a sponsor for the Wonderland: Miami conference.... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its wholly owned KetaDASH will be one of the sponsors of the 2021 Psychedelic Investor Guide. KetaDASH is an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine. “Sponsoring the Psychedelic Investor Guide is a great opportunity for Ehave... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is wholly-owned by KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), to develop the protocol and Informed Consent Form (“ICF”) to support its Institutional Review Board application. CROs... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Psychedelic Stock Review has initiated coverage. “Ehave is about to release a number of digital information tools and services made to enhance the effectiveness and practicality of Psychedelic treatments, for both patients and the medical community,” stated... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it has been included in the 2021 Psychedelic Investor Guide. The Psychedelic Investor Guide covers biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry. Ben Kaplan, Ehave President and CEO stated, “Ehave’s... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today Dr. Rahul Dixit has agreed to join the Company's Medical Advisory Board. As a member of Ehave’s Medical Advisory Board, Dr. Dixit’s primary responsibilities will be to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well as assist... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today its Ehave Covid Passport will be launched in markets worldwide once it completes its beta testing. Ehave's Covid Passport provides small businesses a tool to verify Covid-19 vaccination, and it will empower employers to track vaccination among its employees and... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that it has filed a Form 6-K with the SEC disclosing details of the Company’s LOI to acquire Moksha Digital Software. The Form 6-K filing includes details of the LOI, Fund Utilization, and a High-level Business Plan that includes 5 years of revenue projections.... Read More

Moksha Digital is the creator of the FDA Cleared CuriePACS (Picture Archival and Communication System) and CurieRIS (Radiological Information System) solutions designed to meet the needs of the Radiologists, the Clinicians and the Surgeons. Moksha Digital creates software to help healthcare institutions drive quality higher and costs lower by providing Picture Archival and Communication System (PACS), Radiology Information... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that it has filed a Form 6-K with the SEC disclosing the Company entered into a Research Project Agreement with The University of Melbourne o gather data and bio-markers to target Hallucinogen Persisting Perception Disorder (“HPPD”) on July 2, 2021. Investors can... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has licensed AI technology from Vastminz as another tool to bring the Ehave Dashboard and Ehave Medical App to market. The AI technology to be included in the Ehave Dashboard and Ehave Medical App leverages years of research in artificial intelligence and computer vision to... Read More

MIAMI, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today announced a partnership with a globally recognized university to gather data and bio-markers to target Hallucinogen Persisting Perception Disorder (“HPPD”). The partnership will look to create bio lines and a testing revenue model as well as screening... Read More

HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave believes psychedelics are extremely safe, especially under medical supervision, but believes understanding HPPD will lead to a better understanding of these molecules as a whole Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced a partnership with Health Wizz, a Digital Healthcare IT venture focused on FHIR interoperability and employee wellness, and BurstIQ, the leading provider of blockchain-based data solutions for the healthcare industry. Ehave will use BurstIQ's privacy-protecting technology to link clinical... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the Company Ehave has hired an Institutional Review Board (IRB) as it prepares to launch ketamine clinical Trials in Miami with Tristar Wellness. The IRB will review all research involving human subjects and implement policies and procedures regarding such research. The primary... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today Dr. Bankole A. Johnson has agreed to join the Company's Medical Advisory Board. As a member of Ehave’s Medical Advisory Board, Dr. Johnson’s primary responsibilities will be to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it will be one of four sponsors at PsyTech, an upcoming complimentary Psychedelic Industry summit taking place virtually on July 19-20 for investors and interested individuals. The third annual PsyTech Summit will cover the most heated topics in the psychedelic sector today, like... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, continues its ongoing commitment to strengthen and broaden its capabilities as Dr. Muneer A. Ali joined the Company’s Medical Advisory Board. Dr. Ali will collaborate with other members of Ehave’s Medical Advisory Board to assist and advise the Company on human trials for its cognitive and... Read More

Ehave, Inc. , (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today Dr. Nitin Desai consented to join the Company's Medical Advisory Board. As a member of Ehave’s Medical Advisory Board, Dr. Desai’s main responsibilities will be to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well as assist and... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the appointment of Jeffrey D. Kamlet, MD, FASAM, DABAM to the position of Chief Medical Officer. Dr. Kamlet brings more than 30 years of Internal Medicine, Addiction Medicine and Pain Management experience to Ehave, Inc. during a dynamic time of growth and implementation of... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today its Ehave medical passport will give small businesses a tool to verify Covid-19 vaccination as most small businesses battle to come to terms on how to implement safety precautions. Ehave’s Medical and Vaccine Passport will allow individuals and small businesses to... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced the expansion of its Dashboard capabilities to include data management platform technologies which allow digitally captured information, like electronic health records (EHRs) to be shared. Under the terms of the licensing agreement with Health Wizz, Ehave will... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics. KetaDASH, which is a HIPAA compliant, cloud based platform, will be first to market as a home healthcare provider offering IV based infusion therapy of ketamine. KetaDASH is... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the Company is ahead of schedule and plans launch its KetaDASH www.ketadash.com ketamine IV therapy by the end of the second quarter. In a February 26, 2021 press release Ehave announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter. Ehave... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technology later this year. The clinical trial will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders. The trial, which is designed to enroll... Read More

Ehave, Inc. (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, and Silo Wellness Inc. (CSE: SILO) (“Silo Wellness”), a wellness company in the psychedelics and functional mushroom marketplaces, today announced plans to collaborate on a clinical study in coordination with select volunteer participants of Silo Wellness’ Jamaican psilocybin-facilitated wellness retreats. The... Read More

20/20 Global, Inc. dba Mycotopia Therapies, (OTC Pink: TWGL) (the “Company”), a company focused on psychedelic therapies, announced today it has formed PsyBioMed – Australia and entered into a letter of intent to jointly conduct clinical trials in Australia using psychedelics to treat mental illness. PsyBioMed – Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today CEO and psychedelic thought leader, Benjamin Kaplan, will be featured on the Psychedelic Spotlight segment of New to the Street. The program will air on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST. Shareholders and interested parties are... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has filed application #90549575 on February 26, 2021 with the United States Patent and Trademark Office (USPTO) for a trademark on its KetaDASH brand name. The application has been accepted by the USPTO and will be assigned to an examining attorney. Ehave recently announced plans... Read More

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology. KetaDASH is a personalized mental care platform designed to instantly connect patients with highly skilled nurses to provide ketamine therapy at home under expert... Read More